Who Paid My Doc Search
Menu
Organisation paid for research Program year 2021 Source: CMS Open Payments

Aquiant Research

Neither a doctor nor a teaching hospital

Research payments

$1,126,684

113 payments

Through program year 2021, Aquiant Research is reported as receiving $1,126,684 in research payments, across 113 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $82,328 44
2020 Research $530,171 33
2019 Research $514,185 36

Breakdown

Who paid Research payments · program years 2019–2021
  1. Allergan Inc. $1,063,812 85 payments
  2. Shire North American Group Inc $34,358 19 payments
  3. Ironwood Pharmaceuticals, Inc $17,257 2 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $11,258 7 payments
Studies the money was for Research payments · program years 2019–2021
  1. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $477,604 13 payments
  2. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $346,640 1 payment
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $115,930 14 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $75,418 39 payments
  5. C3718-302 $17,257 2 payments
  6. Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Maintenance $16,955 8 payments
  7. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $15,812 5 payments
  8. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $13,100 4 payments
  9. A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $11,500 3 payments
  10. Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Placebo-Controlled, RW $10,735 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record